secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACURA PHARMACEUTICALS, INC (—)
CIK:        0000786947
Form:       8-K
Filed at:   2026-08-20T19:26:03+00:00
Accession:  0001104659-26-099200
Event type: debt
Sentiment:  negative
Materiality: 0.95
Item codes: 1.01, 2.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acura takes $200K loan from Abuse Deterrent Pharma; warns of bankruptcy risk without more funding by Sept 2026
--------------------------------------------------------------------------------

- Received $200,000 loan from AD Pharma on 8/14/2026; total principal now $11,094,279 with ~$1,290,000 accrued interest.
- Loan bears 5.25% interest, rising to 7.5% on overdue amounts; proceeds used for day-to-day operations.
- Without additional financing by late-September 2026, may furlough staff, scale back operations, or seek bankruptcy protection.
- Company warns of possible complete loss of shareholder value if operations must cease.
- Note and accrued interest currently due/negotiable by December 31, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/786947/000110465926099200/0001104659-26-099200-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/786947/000110465926099200/tm2623715d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-099200

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer